LT2918604T - Vaikų ūminės limfoblastinės leukemijos gydymas - Google Patents

Vaikų ūminės limfoblastinės leukemijos gydymas

Info

Publication number
LT2918604T
LT2918604T LTEP15154416.0T LT15154416T LT2918604T LT 2918604 T LT2918604 T LT 2918604T LT 15154416 T LT15154416 T LT 15154416T LT 2918604 T LT2918604 T LT 2918604T
Authority
LT
Lithuania
Prior art keywords
treatment
lymphoblastic leukemia
acute lymphoblastic
pediatric acute
pediatric
Prior art date
Application number
LTEP15154416.0T
Other languages
English (en)
Lithuanian (lt)
Inventor
Gerhard Zugmaier
Original Assignee
Amgen Research (Munich) Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amgen Research (Munich) Gmbh filed Critical Amgen Research (Munich) Gmbh
Publication of LT2918604T publication Critical patent/LT2918604T/lt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3061—Blood cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Cell Biology (AREA)
  • Hematology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
LTEP15154416.0T 2008-11-07 2009-11-06 Vaikų ūminės limfoblastinės leukemijos gydymas LT2918604T (lt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US11232308P 2008-11-07 2008-11-07
US18329109P 2009-06-02 2009-06-02
US22126909P 2009-06-29 2009-06-29

Publications (1)

Publication Number Publication Date
LT2918604T true LT2918604T (lt) 2018-03-26

Family

ID=41796119

Family Applications (2)

Application Number Title Priority Date Filing Date
LTEP15154416.0T LT2918604T (lt) 2008-11-07 2009-11-06 Vaikų ūminės limfoblastinės leukemijos gydymas
LTEP17206868.6T LT3330293T (lt) 2008-11-07 2009-11-06 Vaikų ūminės limfoblastinės leukemijos gydymas bispecifiniais antikūnais prieš cd3xcd19

Family Applications After (1)

Application Number Title Priority Date Filing Date
LTEP17206868.6T LT3330293T (lt) 2008-11-07 2009-11-06 Vaikų ūminės limfoblastinės leukemijos gydymas bispecifiniais antikūnais prieš cd3xcd19

Country Status (27)

Country Link
US (2) US20110262440A1 (enExample)
EP (4) EP2344539B1 (enExample)
JP (2) JP5798036B2 (enExample)
KR (1) KR101695329B1 (enExample)
CN (2) CN102209729B (enExample)
AU (1) AU2009313039B2 (enExample)
BR (1) BRPI0921341A2 (enExample)
CA (1) CA2742242C (enExample)
CY (3) CY1116160T1 (enExample)
DK (3) DK2918604T3 (enExample)
ES (3) ES2748126T3 (enExample)
HK (1) HK1255590B (enExample)
HR (3) HRP20150400T1 (enExample)
HU (3) HUE025452T2 (enExample)
IL (1) IL212651A (enExample)
LT (2) LT2918604T (enExample)
MX (1) MX2011002931A (enExample)
NO (1) NO2918604T3 (enExample)
NZ (1) NZ591312A (enExample)
PL (3) PL2918604T3 (enExample)
PT (3) PT2344539E (enExample)
RS (3) RS53980B1 (enExample)
RU (3) RU2536933C2 (enExample)
SG (1) SG195549A1 (enExample)
SI (3) SI2344539T1 (enExample)
SM (3) SMT201800149T1 (enExample)
WO (1) WO2010052013A1 (enExample)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6358588A (ja) * 1986-08-29 1988-03-14 Toshiba Corp バ−コ−ド読取装置
DE10254601A1 (de) 2002-11-22 2004-06-03 Ganymed Pharmaceuticals Ag Differentiell in Tumoren exprimierte Genprodukte und deren Verwendung
RS53980B1 (sr) * 2008-11-07 2015-10-30 Amgen Research (Munich) Gmbh Tretiranje akutne limfoblastne leukemije kod dece
ES2565439T3 (es) * 2009-01-09 2016-04-04 Oxford Biomedica (Uk) Ltd Factores
US20150231241A1 (en) * 2012-08-14 2015-08-20 Ibc Pharmaceuticals, Inc. Combination therapy for inducing immune response to disease
JOP20200236A1 (ar) 2012-09-21 2017-06-16 Regeneron Pharma الأجسام المضادة لمضاد cd3 وجزيئات ربط الأنتيجين ثنائية التحديد التي تربط cd3 وcd20 واستخداماتها
HK1209434A1 (en) * 2012-11-13 2016-04-01 Astellas Pharma Inc. Agents for treatment of claudin expressing cancer diseases
TWI635098B (zh) 2013-02-01 2018-09-11 再生元醫藥公司 含嵌合恆定區之抗體
CN103131777A (zh) * 2013-02-05 2013-06-05 南京艾迪康医学检验所有限公司 用于检测e2a-pbx融合基因相对表达量的试剂盒
WO2015121383A1 (en) 2014-02-12 2015-08-20 Michael Uhlin Bispecific antibodies for use in stem cell transplantation
TWI701042B (zh) 2014-03-19 2020-08-11 美商再生元醫藥公司 用於腫瘤治療之方法及抗體組成物
LT3149480T (lt) 2014-05-30 2019-04-25 Amgen Research (Munich) Gmbh B ląstelių pirmtakų ūmia limfoblastine leukemija (all) sergančių pacientų rizikos stratifikacijos būdas
EP3175001B1 (en) 2014-07-30 2021-02-10 Mor Research Applications Ltd. Prognostic methods and systems of treatment for acute lymphoblastic leukemia
WO2016061368A1 (en) * 2014-10-15 2016-04-21 The Children's Hospital Of Philadelphia Compositions and methods for treating b-lymphoid malignancies
SMT202000438T1 (it) 2014-11-17 2020-09-10 Regeneron Pharma Metodi per trattamento di tumore usando l'anticorpo bispecifico cd3xcd20
AU2016215110A1 (en) * 2015-02-05 2017-09-21 Stc.Unm Anti-pre-BCR antagonists and methods
PL3277725T3 (pl) 2015-03-30 2021-06-14 Regeneron Pharmaceuticals, Inc. Regiony stałe łańcucha ciężkiego o zmniejszonym wiązaniu do receptorów Fc gamma
PT3280729T (pt) 2015-04-08 2022-08-01 Novartis Ag Terapias para cd20, terapias para cd22 e terapias de combinação com uma célula que expressa o recetor de antigénio quimérico (car) para cd19
DK3298042T3 (da) * 2015-05-20 2025-02-24 Amgen Res Munich Gmbh B-celledepletering som en diagnostisk markør
KR20180087401A (ko) * 2015-12-22 2018-08-01 리제너론 파아마슈티컬스, 인크. 급성 림프아구성 백혈병을 치료하기 위한 이중특이성 항-cd20/항-cd3 항체
GB201602974D0 (en) * 2016-02-19 2016-04-06 Clube Jasper R Engineered cells & methods (1)
BR112018068628A2 (pt) * 2016-03-14 2019-07-30 Millennium Pharm Inc método de prevenção de doença do enxerto contra hospedeiro
MA45341A (fr) * 2016-06-06 2019-04-10 Hutchinson Fred Cancer Res Procédés de traitement de malignités de lymphocytes b au moyen d'une thérapie cellulaire adoptive
JP2020511462A (ja) 2016-12-03 2020-04-16 ジュノー セラピューティクス インコーポレイテッド キナーゼ阻害剤との組み合わせで治療用ｔ細胞を使用するための方法および組成物
UY37726A (es) * 2017-05-05 2018-11-30 Amgen Inc Composición farmacéutica que comprende constructos de anticuerpos biespecíficos para almacenamiento y administración mejorados
MX2019014268A (es) 2017-06-02 2020-08-03 Juno Therapeutics Inc Artículos de manufactura y métodos para tratamiento usando terapia celular adoptiva.
US12031975B2 (en) 2017-11-01 2024-07-09 Juno Therapeutics, Inc. Methods of assessing or monitoring a response to a cell therapy
KR102083481B1 (ko) 2018-03-22 2020-03-02 강원대학교산학협력단 아연-키토산 나노 입자를 포함한 급성 림프구성 백혈병 치료용 약학조성물
LT3844189T (lt) 2018-08-31 2025-02-25 Regeneron Pharmaceuticals, Inc. Cd3/cd20 bispecifinių antikūnų dozavimo strategija, mažinanti citokinų išsiskyrimo sindromą
BR112021014255A2 (pt) * 2019-01-30 2022-01-18 Wistar Inst Molécula de ácido nucleico, composição, e, método de prevenção ou tratamento de uma doença ou distúrbio
IL322315A (en) 2019-05-14 2025-09-01 Provention Bio Inc Methods and preparations for preventing type 1 diabetes
CU20210096A7 (es) 2019-05-21 2022-06-06 Novartis Ag Moléculas de unión a cd19
TWI809286B (zh) 2019-07-05 2023-07-21 日商小野藥品工業股份有限公司 以pd-1/cd3雙特異性蛋白質所進行之血液性癌症治療
MX2022015872A (es) 2020-06-11 2023-05-16 Provention Bio Inc Metodos y composiciones para prevenir diabetes tipo 1.
IL305188A (en) 2021-02-16 2023-10-01 Childrens Health Care D/B/A Childrens Minnesota Methods for treating B-ALL by administering a pre-BCR complex antagonist
WO2023062188A1 (en) 2021-10-15 2023-04-20 Amgen Research (Munich) Gmbh Subcutaneous administration of cd19-binding t cell engaging antibodies
US20250146017A1 (en) 2023-11-06 2025-05-08 City Of Hope Methods comprising oncolytic viruses expressing cd19t and bispecific t cell engagers
WO2025137344A1 (en) 2023-12-20 2025-06-26 Bristol-Myers Squibb Company Antibodies targeting il-18 receptor beta (il-18rβ) and related methods

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998008875A1 (de) * 1996-08-28 1998-03-05 Viva Diagnostika Diagnostische Produkte Gmbh Kombinationspräparationen und ihre verwendung in der immundiagnostik und immuntherapie
JP4169478B2 (ja) * 1998-04-21 2008-10-22 マイクロメット アーゲー Ｃｄ１９×ｃｄ３特異的ポリペプチドおよびその使用
WO2004106381A1 (en) 2003-05-31 2004-12-09 Micromet Ag Pharmaceutical compositions comprising bispecific anti-cd3, anti-cd19 antibody constructs for the treatment of b-cell related disorders
US8076459B2 (en) * 2003-10-16 2011-12-13 Micromet Ag Multispecfic deimmunized CD3-binders
PT1976886E (pt) 2005-12-16 2015-03-09 Amgen Res Munich Gmbh Meios e processos para o tratamento de doenças tumorais
ES2402591T3 (es) * 2006-08-14 2013-05-07 Xencor Inc. Anticuerpos optimizados que seleccionan como diana CD19
ES2582603T5 (es) * 2008-10-01 2022-12-02 Amgen Res Munich Gmbh Anticuerpos biespecíficos de cadena sencilla con especificidad por antígenos diana de alto peso molecular
RS53980B1 (sr) * 2008-11-07 2015-10-30 Amgen Research (Munich) Gmbh Tretiranje akutne limfoblastne leukemije kod dece
PL2511264T3 (pl) * 2009-01-19 2015-08-31 Abbvie Inc Środki indukujące apoptozę do leczenia raka oraz chorób immunologicznych i autoimmunologicznych
AU2010204555B2 (en) * 2009-01-19 2013-03-07 Abbvie Inc. Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases
CN102459236B (zh) * 2009-05-27 2014-10-29 Abbvie公司 激酶活性的嘧啶抑制剂
CA2771984A1 (en) * 2009-09-20 2011-03-24 Abbott Laboratories Abt-263 crystalline forms and solvates for use in treating bcl-2 protein related diseases
US8840888B2 (en) * 2009-10-27 2014-09-23 Micromet Ag Dosage regimen for administering a CD19XCD3 bispecific antibody

Also Published As

Publication number Publication date
SMT201500104B (it) 2015-07-09
RU2018144313A3 (enExample) 2020-06-15
KR101695329B1 (ko) 2017-01-23
BRPI0921341A2 (pt) 2016-04-26
LT3330293T (lt) 2019-10-10
CN102209729B (zh) 2016-05-25
HK1158667A1 (en) 2012-07-20
RS53980B1 (sr) 2015-10-30
CN102209729A (zh) 2011-10-05
CY1122428T1 (el) 2021-01-27
JP5798036B2 (ja) 2015-10-21
EP3594237A1 (en) 2020-01-15
US20230235053A1 (en) 2023-07-27
PL2344539T3 (pl) 2015-07-31
HK1215258A1 (en) 2016-08-19
DK2344539T3 (en) 2015-05-04
PT2918604T (pt) 2018-03-02
ES2535257T3 (es) 2015-05-07
RS59348B1 (sr) 2019-10-31
SMT201800149T1 (it) 2018-05-02
HUE025452T2 (en) 2016-05-30
HRP20180426T1 (hr) 2018-04-20
RU2014141180A3 (enExample) 2018-06-09
EP2918604B1 (en) 2017-12-20
SMT201900546T1 (it) 2019-11-13
SI2918604T1 (en) 2018-04-30
ES2662929T3 (es) 2018-04-10
AU2009313039A1 (en) 2010-05-14
PL2918604T3 (pl) 2018-05-30
WO2010052013A1 (en) 2010-05-14
RU2018144313A (ru) 2020-06-15
IL212651A (en) 2015-03-31
HRP20191715T1 (hr) 2019-12-13
CY1116160T1 (el) 2017-02-08
KR20110091669A (ko) 2011-08-12
HRP20150400T1 (hr) 2015-05-08
US20110262440A1 (en) 2011-10-27
CN106390114A (zh) 2017-02-15
HUE046222T2 (hu) 2020-02-28
RS56989B1 (sr) 2018-05-31
RU2536933C2 (ru) 2014-12-27
DK3330293T3 (da) 2019-10-07
PT3330293T (pt) 2019-10-18
CA2742242C (en) 2023-01-10
CA2742242A1 (en) 2010-05-14
HK1255590B (en) 2020-07-10
RU2736802C2 (ru) 2020-11-20
CY1120022T1 (el) 2018-12-12
RU2677324C2 (ru) 2019-01-16
SI2344539T1 (sl) 2015-06-30
NZ591312A (en) 2012-09-28
EP3330293B1 (en) 2019-07-24
MX2011002931A (es) 2011-04-11
PL3330293T3 (pl) 2020-02-28
PT2344539E (pt) 2015-04-01
HUE036922T2 (hu) 2018-08-28
EP2344539A1 (en) 2011-07-20
ES2748126T3 (es) 2020-03-13
IL212651A0 (en) 2011-07-31
SG195549A1 (en) 2013-12-30
RU2014141180A (ru) 2016-05-10
JP2012508163A (ja) 2012-04-05
AU2009313039B2 (en) 2015-06-18
EP2918604A1 (en) 2015-09-16
DK2918604T3 (en) 2018-03-19
NO2918604T3 (enExample) 2018-05-19
SI3330293T1 (sl) 2019-10-30
EP3330293A1 (en) 2018-06-06
JP2015232023A (ja) 2015-12-24
RU2011122827A (ru) 2012-12-20
JP6130451B2 (ja) 2017-05-17
EP2344539B1 (en) 2015-02-11

Similar Documents

Publication Publication Date Title
IL212651A0 (en) Treatment of pediatric acute lymphoblastic leukemia
AU2018260815A1 (en) Treatment of Acute Lymphoblastic Leukemia
IL248204A0 (en) Combined treatment of tumors expressing 38cd
ZA201006648B (en) Methods of treatment
NO2016023I1 (no) Glycerol fenylbutyrat
EP2049139A4 (en) TREATMENT OF TUMORS EXPRESSING RAS
HRP20181877T1 (hr) Postupci za liječenje lijekovima koji uklanjaju amonijak
EP2164494A4 (en) Methods of Treatment
GB0723100D0 (en) Treatment of HFnEF
EP2124950A4 (en) PAIN TREATMENT WITH NALOXONE
ZA200807306B (en) Treatment of acute respiratory distress syndrome
GB0814043D0 (en) The treatment of skin disorders
GB0700969D0 (en) Methods of treatment
GB0720136D0 (en) Treatment of blood disorded
GB0809319D0 (en) The treatment of puritus
IL192121A0 (en) Treatment of acute respiratory distress syndrdme
GB0625602D0 (en) Treatment of sialorrhoea
GB0700886D0 (en) Medical treatment
SI2330892T1 (sl) Postopki zdravljenja z uporabo zdravil, ki odstranjujejo amoniak
GB0704989D0 (en) Treatment of influenza
GB0820562D0 (en) Novel use and treatment